Eurofins Technologies (Paris:ERF) recently launched multiple serological assay solutions to detect antibodies targeted against the Nucleocapsid protein of the novel Coronavirus. Antibody tests can be used to identify individuals who have been previously exposed to the virus and in some cases those who have an active infection. However, simple presence of antibodies in an individual does not guarantee immunity to further infections since only a fraction of antibodies provide the ability to neutralize the virus upon a second contact. Currently, elaborate tests requiring high biological safety measures are required to identify these neutralizing antibodies.
Now, a study performed by Eurofins Ingenasa has demonstrated a direct correlation between Eurofins Technologies antibody detection assays and seroneutralization capability of the antibodies detected without the need to perform time-consuming and complex tests including high biological hazard. For this study, 55 blood samples were tested on the INgezim total antibody ELISA and a subset of samples on the VIROTECH SARS-CoV-2 IgG/IgM/IgA ELISA and the results compared to a virus seroneutralization test. This test takes multiple days and includes infection of cell culture with SARS-CoV-2 to detect those antibodies that protect human cells from entering of the virus. In 100% of tested blood samples, the result of the ELISA tests was identical to the seroneutralization assay even though the same result was obtained in less than 2 hours.
Similarly, a study was performed by the NYU Grossman School of Medicine and NYU Langone Health comparing the results of another Eurofins Technologies ELISA using the same technology (GSD SARS-CoV-2 ELISA) to a seroneutralization assay. The study shows a strong correlation between the IgG isotype specific ELISA and the ability of the antibodies in the blood samples to neutralize SARS-CoV-2.
For more information, please visit the Eurofins Technologies webpage
Notes for the editor:
About Eurofins – the global leader in bio-analysis
Eurofins is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in esoteric and molecular clinical diagnostic testing.
With over 48,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005374/en/